Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index; none of the 33 sources its claims cite is checked for support yet.
Abstract
BACKGROUND: Malaria is a complex disease, which varies in its epidemiology and clinical manifestation. Although artemether-lumefantrine has been used as first-line drug for uncomplicated Plasmodium falciparum malaria in Bahir Dar district since 2004, its efficacy has not yet been assessed. The main objective of this study was to quantify the proportion of patients with uncomplicated falciparum malaria who were prescribed artemether-lumefantrine and who failed treatment after a 28-day follow-up. METHODS: The research team attempted to conduct an observational cohort study on the assessment of therapeutic efficacy and safety of artemether-lumefantrine in falciparum malaria patients aged over five years in Bahir Dar district from March to July 2012. RESULTS: Among 130 participants in the study, 60% were males with 1:5 male to female ratio. The mean of asexual parasitaemia load was 8675 parasites/μL and 96.1% participants were free from parasitaemia at day 3. At the end of the study, 98.5% of participants showed adequate clinical and parasitological response of the drug. In the study, only 1.5% of participants were shown late parasitological failure between seventh and 14th day follow-up and 1.3% of participants were free from anaemia at the end of follow-up. CONCLUSION: According to the research findings, artemether-lumefantrine fulfilled the inclusion criteria of WHO as first-line drug and continues to be the drug of choice for the treatment of uncomplicated falciparum malaria. Outputs from this study should be supported through advanced molecular techniques and blood concentration and pharmaco-vigilance of the drug.
Overview
CoChat Summary
TL;DR
In a 28-day observational cohort in Bahir Dar district, Northwest Ethiopia, artemether-lumefantrine achieved a 98.5% adequate clinical and parasitological response among 130 patients with uncomplicated *Plasmodium falciparum* malaria. The drug was well tolerated, with no severe adverse effects beyond FDA-registered events, though the authors call for molecular and pharmacovigilance follow-up.
Key findings
- At day 28, 98.5% of participants showed adequate clinical and parasitological response (abstract; Table 2 reports 128/130, 98.4%); late parasitological failure occurred in 1.5% (2/130) between day 7 and day 14, with no early or late clinical failure reported.
- Mean asexual parasitaemia at day 0 was 8675 parasites/μL; 85.9% and 96.1% of participants were parasite-free at days 2 and 3, respectively, and gametocytes cleared by day 7.
- Mean haemoglobin increased from 10.82 g/dl at day 0 to 11.21 g/dl at day 28; 1.3% of anaemic participants became non-anaemic (≥11 g/dl).
- 32% of participants reported common/typical adverse effects; the most frequent were weakness/fatigue and headache (15.9%), mouth rash (14.7%), and cough (11.5%), with no severe adverse effects recorded beyond FDA-registered events.
Methods
- A 28-day observational cohort study conducted according to the 2009 WHO protocol in Bahir Dar district from March to July 2012; 778 febrile cases were screened, 134 *P. falciparum* mono-infected patients were eligible, and 130 completed follow-up.
- Eligibility included age ≥5 years, parasite density 1000–100,000 parasites/μL, no severe/complicated malaria, no prior antimalarial use, and consent; participants received six supervised doses of AL (20 mg artemether/120 mg lumefantrine) and were followed on days 3, 7, 14, 21, and 28.
- Laboratory assessment used thick/thin Giemsa-stained blood films with parasite counts per 200 leukocytes ×40 and haemoglobin by packed cell volume; analysis used EPI 2002 and SPSS 16 with frequency, chi-square, and logistic regression at α = 0.05.
Limitations
- The paper has no formal limitations section; the conclusion states that outputs should be supported by advanced molecular techniques, blood concentration measurement, pharmacovigilance, and further PCR-based effectiveness studies.
- Evident from the text: single-district observational cohort with 130 completers, no comparator arm, no molecular genotyping to distinguish recrudescence from reinfection, and no drug-level measurement.
- The text also shows minor internal inconsistencies in reported efficacy (98.5% in the abstract, 98.4% in Table 2, 98.3% in the discussion) and in the stated sex ratio.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 13 Not checked · 28 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“1.3 % of participants were free from anaemia at the end of follow-up.”
- Also stated in: § Results · plain
“1.3 % anaemic participants became non-anaemic (≥11 g/dl).”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Abstract > Results
plainn = 130- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“96.1 % participants were free from parasitaemia at day 3.”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Abstract > Results
plainn = 130- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the presence of any side effects was statistically insignificant with age and sex (P > 0.15, 95 % CI).”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, only 32 % of study participants showed common and typical types of adverse effects”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“only 1.5 % of participants were shown late parasitological failure between seventh and 14th day follow-up”
- Also stated in: § Results · plain
“only 1.5 % (2/130) of participants showed late parasitological failure in between the seventh and 14th day of follow-up”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Abstract > Results
plainn = 130- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
13 more claims
Create a free account to see all 42 claims and to verify the 33 references still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 13
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Total analysis | 42 | 29 | 29 | 16 | 14 | 130 | | Withdrew | 2 | | 0 | 2 | 0 | 5 | | Total | 44 | 29 | 29 | 18 | 14 | 134 |”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Results
Reported 5 · recomputed 4
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Abstract > Results
“60 % were males”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Abstract > Results
“1:5 male to female ratio.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| ACPR | 42 (100) | 29 (100) | 28 (99.2) | 16 (100) | 13 (99.2) | 128 (98.4) |”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Results
Reported 99.2 · recomputed 96.551724
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Discussion
“Parasitaemia was reduced by 60 and 96.1 % at days 2 and 3, respectively, and totally cleared at day 7 of follow-up.”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Results
“On day 7, 132 slides from patients were examined and one person was found to be P. falciparum positive”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Results
“| 35–44 (16) | M | 9 | 62.56 | 38.71 | 11.81 | 7502.47 | | 35–44 (16) | F | 7 | 51.29 | 38.44 | 11.2 | 10,477.14 |”
§ Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study > Results
“| Day 0 | 10.11 | 11.08 | 10.17 | 12.52 | 10.24 | 10.82 |”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Weltgesundheitsorganisation (2005) · Cited by 3,799
Guidelines for the Treatment of Malaria-2nd Edition
World Health Organization, (. (2010) · IHI Repository · Cited by 1,065
Epidemiology of drug-resistant malaria
Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H., & Meshnick, S. R. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00239-6 · Cited by 817
Sisowath, C., Strömberg, J., Mårtensson, A., Msellem, M., Obondo, C., Björkman, A., & Gil, J. P. (2005) · The Journal of Infectious Diseases · doi:10.1086/427997 · Cited by 377
Nabarro, D. N. (1999) · PubMed · Cited by 311
(1972) · Medicinal Chemistry · doi:10.1016/b978-0-12-688950-5.50009-x · Cited by 301
Assefa, A., Kassa, M., Tadese, G., Mohamed, H., Animut, A., & Mengesha, T. (2010) · Parasites & Vectors · doi:10.1186/1756-3305-3-1 · Cited by 267
Targett, G., Drakeley, C., Jawara, M., von Seidlein, L., Coleman, R., Deen, J., Pinder, M., Doherty, T., Sutherland, C., Walraven, G., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/319689 · Cited by 239
Lefèvre, G., Looareesuwan, S., Treeprasertsuk, S., Krudsood, S., Silachamroon, U., Gathmann, I., Mull, R., & Bakshi, R. (2001) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.2001.64.247 · Cited by 178
President's Malaria Initiative
Stoops, C. A. (2008) · Cited by 98
Research works printed but not linked: 1
- Africa-focused bulletins on malaria. Dramatic anti-malarial results. 2008. http://www.africafocus.org/country/zambia.php .
Cited by
Marwa, K. J., Kapesa, A., Baraka, V., Konje, E. T., Kidenya, B. R., Mukonzo, J., Kamugisha, E., & Swedberg, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264339 · Cited by 68
Intestinal Permeability of Artesunate-Loaded Solid Lipid Nanoparticles Using the Everted Gut Method
Masiiwa, W. L., & Gadaga, L. L. (2018) · Journal of Drug Delivery · doi:10.1155/2018/3021738 · Cited by 68
Teklemariam, M., Assefa, A., Kassa, M., Mohammed, H., & Mamo, H. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176004 · Cited by 36
Derbie, A., Mekonnen, D. S., Adugna, M., Yeshitela, B., Woldeamanuel, Y., & Abebe, T. (2020) · Journal of Parasitology Research · doi:10.1155/2020/7371681 · Cited by 36
Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis
Gebreyohannes, E. A., Bhagavathula, A. S., Seid, M. A., & Tegegn, H. G. (2017) · Malaria Journal · doi:10.1186/s12936-017-1922-9 · Cited by 29
Metadata
- Authors
- Ebstie, Y. A., Zeynudin, A., Belachew, T., Desalegn, Z., & Suleman, S.
- Affiliations
- Addis Ababa University (ET)
- Jimma University (ET)
- Corresponding author
- Ebstie, Yehenew A.
- Venue
- Malaria Journal
- Published
- 2015-06-05
- Volume
- 14
- Issue
- 1
- Pages
- 236-236
- ISSN
- 1475-2875 (ISSN-L)
- PMC
- PMC4464854
- OpenAlex
- W1552753591
- Cited by
- 24
- References
- 23
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 4
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Malaria Journal (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Greater South Information System
- Funders
- Jimma University (Grant code:ID0EZPAE404)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- artemether-lumefantrine, falciparum malaria, uncomplicated malaria, antimalarial drug efficacy, treatment failure, parasitological response, anemia, drug safety
- MeSH terms
- Artemether, Lumefantrine Drug Combination, Adolescent, Adult, Aged, Antimalarials, Child, Child, Preschool, Drug Combinations, Ethanolamines, Ethiopia, Female, Fluorenes, Humans, Male, Middle Aged, Plasmodium falciparum, Cohort Studies, Malaria, Falciparum, Treatment Outcome, Parasitemia, Artemisinins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. https://app.cochat.ai/papers/10.1186/s12936-015-0744-x
- The paper
- Ebstie, Y. A., Zeynudin, A., Belachew, T., Desalegn, Z., & Suleman, S. (2015). Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. Malaria Journal. https://doi.org/10.1186/s12936-015-0744-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.